Newsroom

Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial

Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor in patients with locally advanced unresectable or metastatic gastrointestinal stromal tumor (GIST).

By |2020-04-28T13:52:38-04:00April 28th, 2020|News|
Go to Top